Effects of repeated doses of a fixed combination oral contraceptive containing 0.075 mg gestodene and 0.03 mg ethinylestradiol on the pharmacokinetics of roflumilast and roflumilast N-oxide

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

An open-label, non-randomized, fixed-sequence study in healthy female subjects.